文献速递细菌感染、耐药与抗菌药物医院感染防控

2007至2016年加拿大MRSA特征分析

Characterization of MRSA in Canada from 2007 to 2016.
PubMed 文献 · J Antimicrob Chemother · 2019-01-01

该研究分析了2007至2016年加拿大医院中社区相关(CA)和医疗相关(HA)MRSA基因型的人口学和分子特征。共鉴定1963株MRSA,来自9103株金黄色葡萄球菌分离株。结果显示MRSA比例从26.1%降至16.9%,CA-MRSA基因型比例从20.8%升至56.3%,2016年CA-MRSA基因型超过HA-MRSA成为最常见类型。

要点

  • 2007至2016年加拿大MRSA占金黄色葡萄球菌比例从26.1%降至16.9%。
  • CA-MRSA基因型比例从20.8%升至56.3%,2016年超过HA-MRSA。
  • PVL在CA-MRSA中占78.4%,在HA-MRSA中仅1.7%。

核心结论

  • 2007至2016年加拿大MRSA比例下降,但CA-MRSA基因型比例持续增加,2016年CA-MRSA基因型超过HA-MRSA成为MRSA感染最常见原因。

研究设计与样本

  • 研究纳入2007至2016年加拿大三级医疗中心住院和门诊患者中收集的9103株金黄色葡萄球菌,鉴定出1963株MRSA。
  • 采用肉汤微量稀释法按CLSI标准(M7第11版,2018)进行药敏试验,PCR检测PVL基因,spa分型进行分子分析。

主要发现

  • MRSA占金黄色葡萄球菌的年比例从2007年的26.1%降至2016年的16.9%(P < 0.0001)。
  • CA-MRSA基因型比例从2007年的20.8%显著增至2016年的56.3%(P < 0.0001),HA-MRSA基因型从79.2%降至43.8%(P < 0.0001)。
  • 主要基因型包括HA基因型CMRSA2(USA100/800)占53.6%和CA基因型CMRSA10(USA300)占24.9%。
  • PVL存在于30.1%的MRSA分离株中,包括78.4%的CA-MRSA和1.7%的HA-MRSA基因型。
  • 对克拉霉素、克林霉素、甲氧苄啶/磺胺甲噁唑和氟喹诺酮类的耐药性随时间显著下降(P < 0.0001)。

临床怎么用

  • 临床应关注CA-MRSA基因型(尤其CMRSA10/USA300)在加拿大医院感染中占比上升的趋势。
  • PVL在CA-MRSA中高携带率提示可考虑对其进行检测以辅助临床评估。
  • 克拉霉素、克林霉素、甲氧苄啶/磺胺甲噁唑和氟喹诺酮类耐药性下降,可为经验性用药提供参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study assessed the demographic and molecular characteristics of community-associated (CA) and healthcare-associated (HA) MRSA genotypes in Canadian hospitals between 2007 and 2016. METHODS: A total of 1963 MRSA were identified among 9103 Staphylococcus aureus isolates collected from inpatients and outpatients presenting to tertiary-care medical centres across Canada. Antimicrobial susceptibility testing was performed by broth microdilution in accordance with CLSI standards (M7 11th edition, 2018). PCR was performed to detect the Panton-Valentine leucocidin (PVL) genes and molecular analysis was performed by spa typing. RESULTS: Between 2007 and 2016, the annual proportion of S. aureus that were MRSA decreased from 26.1% to 16.9% (P < 0.0001). The proportion of CA-MRSA genotypes increased significantly from 20.8% in 2007 to 56.3% in 2016 (P < 0.0001) while HA-MRSA genotypes decreased from 79.2% to 43.8% throughout the study period (P < 0.0001). Predominant genotypes included HA genotype CMRSA2 (USA100/800) (53.6%) and CA genotype CMRSA10 (USA300) (24.9%). PVL was present in 30.1% of all MRSA isolates, including 78.4% of CA-MRSA and 1.7% of HA-MRSA genotypes. Resistance to clarithromycin, clindamycin, trimethoprim/sulfamethoxazole and fluoroquinolones decreased significantly over time (P < 0.0001). CONCLUSIONS: The proportion of MRSA in Canada declined between 2007 and 2016. In contrast, the proportion of CA-MRSA strain types, particularly CMRSA10 (USA300), continues to increase. In 2016, CA-MRSA genotypes surpassed HA-MRSA as the most common cause of MRSA infections in Canadian hospitals.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Nichol KA, Adam HJ, Golding GR, et al. Characterization of MRSA in Canada from 2007 to 2016. J Antimicrob Chemother. 2019. PMID: 31505646. doi:10.1093/jac/dkz288

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。